Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433408 | 0.89 | MGLL (0.43) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL126701 | 0.88 | LMNA (0.45) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL123859 | 0.87 | MGLL (0.42) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL5717652 | 0.87 | PARP1 (0.46) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL13312285 | 0.87 | MGLL (0.44) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL11909549 | 0.83 | LMNA (0.50) | KDM4ELMNAMEN1KMT2ADHODH | |
| SCHEMBL973413 | 0.83 | ALOX15 (0.45) | KDM4EKMT2AMGLLTDP1ALDH1A1 | |
| SCHEMBL123322 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1NFKB1MAPTTSHR | |
| SCHEMBL30813138 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1NFKB1MAPTTSHR | |
| SCHEMBL2192041 | 0.79 | MGLL (0.40) | KDM4ELMNAMEN1KMT2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| CN-102006777-B | Herbicidal compounds | SYNGENTA LTD | 2015-04-01 | — | — | CN | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| CN-1835944-A | Quinolyl amide derivatives as CCR-5 antagonists | SCHERING AG (DE) | 2006-09-20 | — | — | CN | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | CCRL2, CCR5, CCR1 | KDM4E 2423/4885LMNA 4593/4885MEN1 4608/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | KDM4E 3779/4885LMNA 2887/4885MEN1 3708/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885LMNA 1845/4885MEN1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.